President & Fellows of Harvard College v. Lee

589 F. App'x 982
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 29, 2014
Docket2013-1628
StatusUnpublished
Cited by4 cases

This text of 589 F. App'x 982 (President & Fellows of Harvard College v. Lee) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
President & Fellows of Harvard College v. Lee, 589 F. App'x 982 (Fed. Cir. 2014).

Opinion

MOORE, Circuit Judge.

The President and Fellows of Harvard College and E.I. du Pont de Nemours and Company (collectively, Harvard) appeal from the district court’s grant of summary judgment affirming the United States Patent and Trademark Office’s (PTO) finding that U.S. Patent No. 5,925,803 had expired as a result of a terminal disclaimer and refusal to enter new claims during the reexamination of the patent on that basis. Because the district court properly found that the PTO’s determination that the patent had expired was not arbitrary, capricious, an abuse of discretion, or contrary to law, we affirm.

BACKGROUND

This appeal relates to the family of patents directed to the “Harvard mouse” inventions. These patents disclose inventions related to a transgenic research animal (preferably a rodent such as a mouse) with an activated oncogene sequence, i.e., a gene sequence which, when incorporated into the genome of the animal, makes the animal highly susceptible to developing cancer. U.S. Patent No. 4,736,866, col. 1, 11. 31-42; U.S. Patent No. 5,087,571, col. 1, 11. 35-46; '803 patent, col. 1 11. 35-39. The '866 patent was the first Harvard Mouse patent.

The second Harvard Mouse patent, the '571 patent, was filed as a divisional of the '866 patent. During prosecution of the '571 patent, the PTO rejected certain claims for obviousness-type double patenting in view of the claims of the '866 patent. Harvard responded to the double patenting rejection by filing a terminal disclaimer; it made no substantive arguments against the rejection except for pointing to the terminal disclaimer. Harvard’s terminal disclaimer disclaimed any portion of the term “of any patent granted on the above-identified application or on any application which is entitled to the filing date of this application under 35 U.S.C. § 120.” J.A. 1271-72 (emphasis added). It stated that the applicant intended that it *984 “run with any patent so granted” and that it bind any of its successors or assignees. Id. The terminal disclaimer also stated that “[accompanying this disclaimer is the fee set forth in 37 C.F.R. § 1.20(d).” J.A. 1272. In its submission to the PTO, which included the terminal disclaimer, Harvard authorized the PTO to charge any fees to its attorney’s deposit account. Upon receipt of the terminal disclaimer, the PTO . placed a copy in the official prosecution history of the '571 patent and withdrew its obviousness-type double patenting rejection, “in view of Applicant’s arguments.” J.A. 5347.

The '803 patent at issue in this case is the third Harvard Mouse patent and was filed as a continuation of the '571 patent. During an ex parte reexamination of the '803 patent, the examiner rejected the claims on double patenting grounds and found that the '803 patent had expired based on the terminal disclaimer filed during prosecution of the '571 patent. In response to the PTO’s rejection, Harvard filed an amendment adding several new claims, arguing that the '803 patent had not expired based on the terminal disclaimer and that the double patenting rejection was improper. In the next office action, the examiner withdrew the claim rejections and issued a notice of intent to issue a reexamination certificate for the original claims of the '803 patent. However, the examiner refused to allow Harvard to add new claims, reasoning that the '803 patent had expired based on the terminal disclaimer entered during prosecution of the '571 patent and that new claims cannot be entered into an expired patent. See 37 C.F.R. § 1.530(j).

Harvard petitioned the PTO Director for review, challenging the examiner’s finding. It argued, in relevant part, that there was no evidence that it had paid the requisite terminal disclaimer fee and that, as a result, the terminal disclaimer was not legally entered into the prosecution history for the '571 patent and was therefore invalid. The Director dismissed Harvard’s petition, finding that the terminal disclaimer was properly recorded and remained in effect, and that thus, the '803 patent had expired.

Harvard filed an Administrative Procedure Act (APA) action in district court challenging the PTO’s refusal to enter the new claims on the ground that the '803 patent had expired. The district court granted summary judgment in favor of the PTO finding that the PTO’s factual determination that Harvard submitted the requisite fee with the terminal disclaimer was not arbitrary or capricious or contrary to the law. President and Fellows of Harvard College v. Rea, No. 12-1034, 2013 WL 2152635, at *5 (E.D.Va. May 15, 2013). Harvard appeals. We have jurisdiction under 28 U.S.C. § 1295(a)(1).

Discussion

We review a district court’s grant of summary judgment de novo, applying the same standard as the district court. Burandt v. Dudas, 528 F.3d 1329, 1332 (Fed. Cir.2008). Accordingly, with respect to actions brought under the APA, we will “hold unlawful and set aside agency action, findings, and conclusions found to be arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.” 5 U.S.C. § 706(2)(A). The burden of showing the agency action was arbitrary and capricious lies with the plaintiff. See Ohio Valley Envtl. Coal. v. Aracoma Coal Co., 556 F.3d 177, 192 (4th Cir.2009).

Harvard argues that the PTO’s finding that the '803 patent had expired as a result of the terminal disclaimer was arbitrary and capricious. Harvard argues that to create an effective, valid terminal disclaimer, a patent applicant must pay the fee required by law. 35 U.S.C. § 253 *985 (1975); 37 C.F.R. § 1.321(b) (1989). In this case, it contends that the evidence establishes that Harvard failed to pay the required terminal disclaimer fee when it •submitted its terminal disclaimer in 1989. First, Harvard argues that it provided evidence in the form of a declaration from the attorney who handled prosecution of the '571 patent stating that he did “not believe that a check for payment of the [t]erminal [disclaimer fee was [filed].” J.A. 5250. He testified that his file for the '571 patent did not contain a copy of a check for the terminal disclaimer fee, and that his standard practice included placing a copy of any check submitted to the PTO in his files specific to the patent. Id. He also testified that he could not find any other evidence in his files showing that a check had been submitted.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Schindler v. Vidal
E.D. Virginia, 2025
DRIT LP v. Glaxo Group Limited
Superior Court of Delaware, 2023
Aguilar v. United States
124 Fed. Cl. 9 (Federal Claims, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
589 F. App'x 982, Counsel Stack Legal Research, https://law.counselstack.com/opinion/president-fellows-of-harvard-college-v-lee-cafc-2014.